glp-1 and pancreatic cancer Glucagon-like peptide-1 receptor agonists risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials Glucagon-like Peptide 1 Receptor Signaling

Nutritional Neuroscience, 25 (1), 6469

STEP series clinical trials of Semaglutide Novo's two obesity products, Wegovy and Saxenda, have generated DKK 16.86bn (USD 2.5bn) in sales throughout 2022, doubling the preceding year's result of DKK 8.4bn (USD 1.2bn) an increase of 101%

Proc Natl Acad Sci U S A 89: 8641-8645, 1992

Because both GIP and GLP-1 pathways influence appetite, reward, and metabolism, ZepBound targets multiple drivers of weight gain simultaneously

Companies like Noom and Hims have also launched programs to prescribe microdosed GLP-1s, claiming that these smaller doses can reduce metabolic risk, lower inflammatory markers, and even lower the risk of cognitive decline. Evidence of sustained patient use post-shortage: Prescription volume and utilization of compounded semaglutide and tirzepatide have continued to grow despite the end of medication shortages, suggesting that compounders may be leveraging additives or dosage adjustments to justify production

Nausea, burping , and general stomach discomfort peak within 1 to 3 hours of injection